Bouncing back from the 2022 infant formula crisis with a clear strategic emphasis on infant formula and bioactive production, we have witnessed companies such as DSM and IFF receive HMO approval on the Chinese market, alongside Yali Bio’s transformative OPO production changing the future face of formula as we know it.

With this momentum signifying the industry taking a step forward in bridging the gap towards the holy grail of human milk, the Bioactive Infant Formula & Nutrition Summit is uniquely positioned in collating such experts to define the pathway to streamline functionality, translational science and regulatory excellence. 

Join regulatory specialists, nutrition experts, and medical affairs leads to:

• Unite with formula manufacturers, novel food biotechs and ingredient providers to uncover novel bioactive opportunities and innovative technologies
• Conceptualize regulatory GRAS status and safety reviews to safeguard formula products alongside industry regulatory specialists
• Smoothen preclinical and clinical translation to regulators, stakeholders and consumers to support efficacy claims 
• Advance product functionality for HMOs, MFGMs and novel bioactives to enhance humanization

Built in collaboration with Abbott, FrieslandCampina, and Bobbie, this is your time to be part of the movement towards quality, nutritional formula.